Blends
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as BPC-157 + TB-500, Wolverine blend, BPC-TB
Routes represented in the knowledgebase: Subcutaneous (SubQ).
BPC-157 / TB-500 is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
BPC-157 / TB-500, sold by some vendors as the Wolverine blend, is a fixed-ratio compounded preparation containing two research peptides in one vial. BPC-157 is a synthetic 15-amino-acid peptide whose sequence derives from a protein found in human gastric juice, developed at the University of Zagreb and described in animal work as cytoprotective and angiogenic. TB-500 is a short synthetic fragment of thymosin beta-4, usually the actin-binding segment LKKTETQ, sometimes acetylated. Sellers pair them on the rationale that one is associated with growth-factor and nitric oxide signaling and the other with actin-mediated cell migration, but the pairing is a commercial convention rather than a studied formulation.
Fixed-ratio compounded blends carry no combined trial evidence, and this one is no exception: no published clinical trial, and no published animal study, has tested BPC-157 and TB-500 administered together as a single product. Evidence for the parts does not transfer to the mixture, and the parts are themselves weakly evidenced. Published human data on BPC-157 amount to a few small reports and a Phase I oral trial registered in 2015 whose status is listed as unknown with no results posted, while a 2025 systematic review in orthopaedic sports medicine found no high-quality human evidence. No human clinical trial of TB-500 has been published at all.
Regulators treat products of this kind as unapproved compounded preparations rather than as medicines. Neither component is approved in any country, and in 2023 the FDA placed BPC-157, thymosin beta-4, and the TB-500 fragment on its list of bulk drug substances that may present significant safety risks when compounded, citing immunogenicity, peptide-related impurities, and inadequate safety information, which removes them from routine compounding under section 503A. Both are also prohibited in sport: BPC-157 has been named on the WADA Prohibited List since the 2022 edition under S0, non-approved substances, and thymosin beta-4 and its derivatives, with TB-500 given as the example, fall under S2.
The blend is supplied as a lyophilized powder in a single vial that is reconstituted before subcutaneous injection, so the two peptides share one solution at a ratio set by the seller. That ratio is not standardised, is not verified by any regulator, and cannot be reconstructed after reconstitution, which is why an inventory record for a blend usually captures total peptide mass per vial and the stated split between components alongside lot, reconstitution date, and storage temperature. No approved label governs beyond-use time, no stability data cover the two peptides in one solution, and identity and purity of research-grade material are not independently verified.
Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.
A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
NAD+ and BPC-157 are proposed as complementary for cellular-energy and tissue-repair goals, but no direct animal or human combination study has established synergy or safety.
Interaction evidence sourceNAD+ evidence reviewFDA BPC-157 safety assessmentAn exploratory rat Achilles-tendon study found improved histology versus control for the combination, but no additional benefit over either peptide alone.
Interaction evidence sourceFDA TB-500 assessmentThe pair is proposed as complementary from separate preclinical findings involving tendon repair, angiogenic signaling, collagen, and extracellular-matrix accumulation.
Interaction evidence sourceGHK-Cu wound studyFDA peptide safety overviewThe pair is proposed as complementary from separate evidence involving thymosin-beta-4-related cell migration and GHK-Cu-associated matrix accumulation.
Interaction evidence sourceGHK-Cu wound studyFDA TB-500 assessmentThe pair is proposed as complementary from separate preclinical evidence for tissue repair and reduced inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentThe pair is proposed as complementary through separate preclinical rationales involving tissue migration, remodeling, and inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentNo. Neither BPC-157 nor TB-500 is an approved medicine in any country, and no regulator has reviewed a product combining them. In 2023 the FDA placed both on its list of bulk drug substances that may present significant safety risks when compounded, which excludes them from routine compounding under section 503A. Vials sold under this name are research-grade material or unapproved compounded preparations.
Wolverine blend is a vendor nickname for a vial containing BPC-157 and TB-500 together, borrowed from the comic-book character associated with rapid healing. It is a marketing label rather than a defined formulation: the mass ratio between the two peptides differs between sellers, and neither the name nor the ratio corresponds to anything in the published literature or to a reviewed product specification.
No published study has tested the two peptides administered as one product, in people or in animals. The literature treats them separately, and the FDA assessed them separately when it added each to its compounding safety-risk list in 2023. Findings reported for BPC-157 in rodent tendon, muscle, and gut models and for full-length thymosin beta-4 in wound models do not establish anything about the mixture.
Yes, on both counts. The WADA Prohibited List named BPC-157 in its 2022 edition as an example under S0, non-approved substances, and lists thymosin beta-4 and its derivatives, with TB-500 given as the example, under S2 peptide hormones and growth factors. Both categories are prohibited at all times, in and out of competition, and anti-doping laboratories have published detection methods for TB-500 and its metabolites.
Because both peptides dissolve into one solution, a dose log entry cannot separate them afterwards. Records for blends therefore tend to note the total peptide mass per vial, the component split stated by the seller, the lot number, the reconstitution date, the resulting concentration, the route and injection site, and any reaction, which are the details an adverse-event report or an anti-doping inquiry would ask for.
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.
